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ABSTRACT
Use of dual antiplatelet therapy (DAPT; the
combination of aspirin and an inhibitor of
platelet P2Y12) is the key pharmacological
component in the management of acute
coronary syndrome and percutaneous coronary
intervention (PCI) with stent implantation, but
the optimal treatment duration is still unclear.
Although current guidelines recommend
prescription of DAPT for at least 12 months after
implantation of drug-eluting stents (DES) if
patients are not at high risk of bleeding, several
studies showed conflicting results. Observational
studies have shown inconsistent findings (i.e.,
some studies suggested longer duration would be
better, and others vice versa) and small-to-
moderate sized randomized clinical trials
suggested that prolonged use of DAPT beyond
12 months would not be more beneficial and
could be detrimental in safety outcomes.
However, these studies suffer from insufficient
statistical power, data from old version of DES,
and non-uniform duration of DAPT. Given there
might be the relative risk and benefit associated
with combination of DES use and DAPT
prescription, the optimal decision making with
regard to DAPT duration would be essential for
patients who underwent PCI with DES. Thus, by
understanding and comparing the evidences of
recent studies that support for shorter and longer
duration of DAPT, we sought to guide the treating
physician in deciding optimal duration of DAPT
in such patients. Up to now, there is no strong
evidence supporting that longerdurationofDAPT
is better than shorter duration of DAPT in terms of
efficacy and safety outcomes after DES placement.
Keywords: Coronary artery disease; Drug-
eluting stent; Dual antiplatelet therapy;
Percutaneous coronary intervention
INTRODUCTION
Many randomized clinical trials have
demonstrated better efficacy of drug-eluting
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stents (DESs) in reducing restenosis and rate of
repeat revascularization as compared with bare-
metal stents (BMSs) [1, 2]. Although DESs were
widespread and worked as a default device
strategy in the majority of patients receiving
percutaneous coronary intervention (PCI) for
more than a decade, there was a considerable
concern regarding late stent thrombosis (ST) [3–
6]. Pathologic studies suggested that incomplete
endothelialization of DESs was frequently
observed even after 6 or 12 months after PCI
[7–9], and clinically, most of thrombotic events
tended to occur in the first 6–12 months after
procedure and sometimes happened after the
first year after DES implantation [5, 6]. As a
result, prolonged use of dual antiplatelet
therapy (DAPT) has become prevalent in
clinical practice; however, careful balancing
between ischemic benefits and bleeding risks
according to the duration of DAPT has been an
issue for several years [10–12].
On the basis of cumulative evidence, the
current guidelines recommend that DAPT
should be given either for 6–12 months
(European guidelines [13]) or for at least
12 months (U.S. guidelines [14]) after DES
implantation unless patients are at high risk
for bleeding. However, these recommendations
are largely based on registry data and
randomized trials with a limited number of
patients, and therefore the optimal duration of
DAPT remains in question. Up to recently,
several clinical studies have been performed to
address questions about the optimal duration
of DAPT in patients who have received DESs
[15–21]. This article systemically reviews the
current evidence from available clinical studies
with the aim of helping physicians to make
decisions on the optimal duration of DAPT
for patients who are undergoing DES
implantation.
METHODS
PubMed, Embase, and the Cochrane Central
Register of Controlled Trials (CENTRAL) were
searched for randomized clinical trials and
prospective or retrospective observational
studies published between January 2002 and
June 2014. Search terms were: ‘‘coronary artery
disease’’, ‘‘clopidogrel’’, ‘‘drug-eluting stents’’,
‘‘dual antiplatelet therapy’’, and ‘‘percutaneous
coronary intervention’’. Reference lists of review
articles, meta-analyses, and original studies
identified by the electronic searches were also
checked to find other eligible studies for
systemic reviews. In addition, conference
proceedings/abstracts from the American Heart
Association, American College of Cardiology,
Transcatheter Cardiovascular Therapeutics,
Society of Cardiovascular Angiography and
Intervention, European Society of Cardiology,
and Euro-PCR were searched. There was no
language restriction for the search. We excluded
studies with number of enrolled patients less
than 500. The search process was fairly
extensive, and efforts were made to obtain the




There were several observational studies (not,
randomized clinical trials) that supported
relatively longer duration, more than
12 months of DAPT after DES implantation.
Those were mostly from the early experiences of
DESs which implies that these were data from
the first-generation DES. Brief summary of each
study design and primary results are
summarized in Table 1 [22–26].
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A first safety concern with regard to DES
implantation without long-term maintenance
of clopidogrel was raised by data from the
Basel Stent KostenEffektivita¨ts Trial—Late
Thrombotic Events (BASKET-LATE)
(ISRCTN75663024) [22]. This study intended
to define the incidence of late clinical events
[cardiac death or myocardial infarction (MI)]
and late ST in patients treated with the first-
generation DESs versus BMSs after the
discontinuation of clopidogrel and showed
that more thrombotic events were found to
occur 7–18 months after the procedure during
the period with absence of DAPT, which were
twice as frequent after DESs than BMSs. A
subsequent, observational study from Duke
registry highlighted the apparent benefits of
extended clopidogrel use after first-generation
















































































12 Adjusted HR 0.75,
p = 0.0155
ACS acute coronary syndrome, BMS bare-metal stents, CVA cerebrovascular accident, DAPT dual antiplatelet therapy, DES
drug-eluting stents, HR hazard ratio, MI myocardial infarction, PCI percutaneous coronary intervention, SA stable angina,
ST stent thrombosis
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DES implantation [23]. In patients who
continued clopidogrel for more than 6 or
12 months after DES placement, adjusted rates
of death or MI at 24 months were significantly
lower as compared with those in patients who
did not continue clopidogrel (3.1% vs. 7.2%,
p = 0.02). Patients in the BMS group had similar
long-term mortality and rates of death/MI
regardless of duration of clopidogrel at both
landmark time points. In the Dutch registry,
albeit in small numbers of DES patients, early
discontinuation of clopidogrel, less than
12 months after the index PCI, was suggested
as a strong predictor of ST [hazard ratio (HR):
5.9, 95% confidence interval (CI) 1.7–19.8] [24].
Similarly, in the Melbourne Interventional
Group registry, 12 months of DAPT resulted
in reduced mortality than a shorter duration
(B6 months) of DAPT (2.8% vs. 5.3%, p = 0.012)
[25]. The SWEDEHEART(NCT01623700) registry
data showed that[6 months of DAPT compared
with 6 months of DAPT among acute coronary
syndrome (ACS) patients was associated with a
lower risk of death, stroke, or re-infarction (HR
0.75, 95% CI 0.59–0.95) [26]. Even in the
subgroup analysis, with less than 6-month
duration of DAPT, more than 3 months of
DAPT lowered the risk of death, stroke, or
re-infarction (HR 0.84, 95% CI 0.75–0.95)
compared to less than 3 months of DAPT.
Shorter Is Better
By contrast, some observational studies and
randomized trials suggested the safety and
efficacy of shorter duration (less than
6–12 months) of DAPT would be comparable
or better in safety outcomes compared to longer
duration of DAPT among patients receiving DES
implantation. Summary of these studies is
shown in Table 2 [4, 5, 16–21, 27].
Observational Studies
Airoldi et al. [4] suggested that discontinuation
of thienopyridine therapy was the key
determinant of ST occurrence within the first
6 months, but not longer than 6-month period.
They suggested that a vulnerable period of ST
associated with DAPT continuation would be
within 6 months. Schulz et al. [5] also
demonstrated that the discontinuation of
clopidogrel was a strong predictor for ST
within the first 6 months but not thereafter
after the first-generation DES implantation. The
Two-Year Clopidogrel Need (TYCOON) study
which is also based on the first-generation DES
data, suggested that there was no long-term
survival benefit in 24 months of DAPT
compared to 12 months of DAPT, although
early discontinuation of DAPT was the
important predictor of ST (1% vs. 3%,
p = 0.02) [27].
Randomized Trials
Several randomized clinical trials demonstrated
no reduction in death or MI with prolonged
DAPT compared to standard or shorter duration
of DAPT use. The first randomized trial,
Evaluation of the Long-Term Safety after
Zotarolimus-Eluting Stent, Sirolimus-Eluting
Stent, or Paclitaxel-Eluting Stent Implantation
for Coronary Lesions—Late Coronary Arterial
Thrombotic Events [ZEST-LATE
(NCT00590174)]/Correlation of Clopidogrel
Therapy Discontinuation in Real-World
Patients Treated with Drug-Eluting Stent
Implantation and Late Coronary Arterial
Thrombotic Events [REAL-LATE
(NCT00484926)] randomized patients who
were event free within 1 year after DES
implantation to receive DAPT or aspirin alone
[17]. At 24 months, no difference was observed
in the primary endpoint (composite of cardiac
death or MI) or the risk for ST. However,
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majority of patients in these trials were treated
with first-generation DES and the observed
event rate was lower than expected, favoring a
shorter duration of DAPT. Subsequently, in the
DES-LATE (NCT01186146) study (extended
study of ZEST-LATE/REAL-LATE), a total of
5,045 patients were randomized to either
DAPT continuation or aspirin alone after
1 year of DES implantation [18]. After
12 months, DAPT compared to aspirin alone
showed no benefit in preventing ST (HR 1.59,
95% CI 0.61–4.09, p = 0.34), MI (HR 0.96, 95%
CI 0.63–1.48, p = 0.86), or death (HR 0.71, 95%
CI 0.45–1.10, p = 0.12). Incidence of major
bleeding events between two groups was
similar up to 24 months, but longer follow-up
after 24 months revealed higher incidence of
bleeding events in the DAPT continuation
group (HR 0.67, 95% CI 0.47–0.95, p = 0.026).
The Prolonging Dual Antiplatelet Treatment
after Grading Stent-induced Intimal
Hyperplasia [PRODIGY(NCT00611286)] trial
provided a major next step to answer this issue
by including more diverse stent types (BMSs,
first- and second-generation DESs) and by
shortening the duration DAPT into 6 months
[20]. They randomized more than 2,000
patients to receive either 6 or 24 months of
DAPT among patients who received a thin-strut
BMS, a paclitaxel-eluting stent (PES), a
zotarolimus-eluting stent (ZES), or an
everolimus-eluting stent (EES) and therapy.
There was no difference in the primary
endpoints [the composite of death from any
cause, MI, or cerebrovascular accident (CVA)]
between the two groups. However, there was an
excess of bleeding in patients assigned to
24 months of DAPT.
The Efficacy of Xience/Promus versus Cypher
to Reduce Late Loss After Stenting [EXCELLENT
(NCT00698607)] trial compared shorter
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following DES implantation [16]. This study
population predominantly received an EES
(Xience or Promus, 74.8%) and rest of the
patients received sirolimus-eluting stent (SES)
(25.2%). The rate of target-vessel failure (TVF)
(composite of cardiac death, MI, or ischemia-
driven TVR) at 12 months was 4.8% in the
6-month DAPT group and 4.3% in the
12-month DAPT group (p = 0.001). Although
ST tended to occur more frequently in the
6-month DAPT than 12-month DAPT (0.9% vs.
0.1%, HR 6.02; 95% CI 0.72–49.96; p = 0.10),
the risk of death or MI did not differ between
the two groups.
The REal Safety and Efficacy of 3-month
DAPT following Endeavor zotarolimus-eluting
stent implantation [RESET (NCT01145079)]
trial compared the safety and efficacy of
shorter duration (3 months) of DAPT and
standard duration of 12 months of DAPT after
Endeavor zotarolimus-eluting stent (E-ZES)
implantation [19]. Three-month DAPT was
shown to be non-inferior to the standard
12-month therapy with respect to the primary
endpoint (cardiac death, MI, ST, TVR, or
bleeding).
Recently, the OPTIMIzed duration of
clopidogrel therapy following treatment with
the zotarolimus-eluting stent in real-world
clinical practice [OPTIMIZE (NCT01113372)]
trial, which included 3,119 patients with
stable coronary artery disease or low-risk ACS
treated with ZES to compare 3 versus 12 months
of DAPT, suggested that 3 months of DAPT was
non-inferior to 12 months of DAPT for reducing
net adverse clinical and cerebral events (a
composite of all-cause death, MI, stroke, or
major bleeding), without significantly
increasing the risk of ST [21].
A meta-analysis of four randomized trials
(REAL/ZEST-LATE, PRODIGY, EXCELLENT,
RESET) was performed and the median DAPT
duration was 16.8 months in the extended
group versus 6.2 months in the control group
[28, 29]. During follow-up, extended DAPT did
not provide more clinical benefit [no difference
in mortality, odds ratio (OR) 1.15, 95% CI
0.85–1.54; MI, OR 0.95, 95% CI 0.66–1.36; and
ST, OR 0.88; 95% CI 0.43–1.81] as compared to
shorter duration of DAPT; however, prolonged
use of DAPT was associated with an increase of
major bleeding (OR 2.64, 95% CI 1.31–5.30).
Consistent findings were obtained in another
meta-analysis, further including the OPTIMIZE
trial [30, 31]. A total of 4,081 patients received
DAPT for 3–6 months, and 4,076 patients were
treated with DAPT for 12–24 months. There was
no significant difference in the rate of the
composite of cardiac death or MI between the
short and prolonged DAPT groups (3.3% vs.
3.0%; OR 1.11, 95% CI 0.87–1.43, p = 0.41). But
major bleeding was significantly higher in the
group of patients treated with prolonged DAPT
(0.29% vs. 0.71%, p = 0.01).
Therefore, current available randomized
clinical trials and meta-analyses suggest that
extension of the duration of DAPT after DES
implantation might increase the risk of
bleeding without reducing ischemic events.
But, considering the limited sample size and
the inclusion of mainly low-risk patients with
low event rates in these trials, still the safety of
short-term DAPT remains uncertain.
Ongoing Randomized Trials
Several unresolved issues and unmet needs with
regard to optimal DAPT duration after DES
placement in clinical practice should be
addressed from large-sized ongoing clinical
trials. The previous, five randomized trials
comprising nearly 10,000 patients indicated
that extended courses of clopidogrel did not
contribute favorably to patient outcomes and
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might in fact be detrimental in terms of safety
outcomes. However, this conclusion would be
too early to make a firm statement due to
several limitations in terms of relatively small
numbers of patients, a low rate of events, and
shorter follow-up period. All of these trials
adopted open-label designs and none of the
trials have been evaluated systematically
according to clinical and anatomic risk
profiles. Therefore, much larger, blinded,
randomized clinical trials would provide more
confirmative answer to determine the optimal
DAPT duration after DES implantation (Table 3)
[32–37].
In the largest scale study to date, the Dual
Antiplatelet Therapy [DAPT (NCT00977938)]
study enrolled more than 20,000 patients
treated with any generation of DES and
approximately 3,000 patients with BMSs to
either 12 or 30 months of DAPT, with patients
stratified according to clinical and angiographic
complexity [32]. Unlike the preceding
randomized trials (except OPTIMIZE), study
therapy was blinded and was masked. The
primary results will be presented in the
upcoming scientific meeting of the American
Heart Association later this year. Another
ongoing trial is The Safety And Efficacy of
6-month Dual Antiplatelet Therapy After Drug-
Eluting Stenting [ISAR-SAFE (NCT00661206)],
which evaluates a 6- or 12-month DAPT among
6,000 patients [33]. And OPTImal DUAL
antiplatelet therapy trial [OPTIDUAL
(NCT00822536)] is ongoing to assess the
efficacy and safety of 12 versus 48 months of
DAPT after DES implantation [34]. In the
assessment with a double randomization of (1)
a fixed dose versus a monitoring-guided dose of
aspirin and clopidogrel after DES implantation,
and (2) treatment interruption versus
continuation, 1 year after stenting [ARCTIC
(NCT00827411)] study, diverse durations of
DAPT based on the platelet function
monitoring is currently under investigation
among 2,500 patients [35].
Currently, an increasing number of patients
are receiving the second-generation P2Y12
inhibitors (prasugrel or ticagrelor) instead of
clopidogrel which demonstrate more potent
suppression of platelet activity, leading to
reduction of recurrent ischemic events [37, 38].
Based on these results, recent guidelines
recommended prasugrel and ticagrelor on
equal terms with clopidogrel in the patient
with ACS or stent implantation [13]. However,
studies on optimal duration of DAPT with these
newer drugs are still very limited. In the
upcoming years, a variety of trials with unique
combinations with newer P2Y12 inhibitors in a
diverse duration could be suggested among
patients who are undergoing PCI with DES
implantation. The MEDTRONIC Endeavor
Drug-Eluting Stenting: Understanding Care,
Antiplatelet Agent and Thrombotic Events
(EDUCATE, NCT01069003) study is designed
to analyze 12 versus 30 months of DAPT; after
12 months of routine DAPT, patients will be
randomly allocated to the placebo, clopidogrel
or prasugrel group. In the clinical study
comparing two forms of antiplatelet therapy
after stent implantation trial [GLOBAL LEADERS
(NCT01813435)], 1 month of ticagrelor plus
aspirin followed by 23 months of ticagrelor
monotherapy will be compared to 12 months
of DAPT followed by aspirin monotherapy.
There was an also effort to figure out the
optimal mode of DAPT discontinuation. The
Abrupt Versus Tapered Interruption of Chronic
Clopidogrel Therapy After DES Implantation
[ISAR-CAUTION (NCT00640679)] study
addressed the question of whether clopidogrel
should be discontinued abruptly or with a
progressive downgraded dosing [36]. Patients
with planned discontinuation of chronic
8 Cardiol Ther (2014) 3:1–12
Table 3 Ongoing trials on duration of dual antiplatelet therapy
Study Total
N (DES)
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1,100 DES 6 vs. 12 m 24 All-cause death, MI, CVA,
bleeding or any revascularization
BMS bare-metal stents, CVA cerebrovascular accident, DAPT dual antiplatelet therapy, DES drug-eluting stents, HR hazard
ratio, MI myocardial infarction, PCI percutaneous coronary intervention, ST stent thrombosis, ZES zotarolimus-eluting
stent
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clopidogrel therapy after DES implantation were
randomized in a double-blinded fashion to
either gradual discontinuation (according to a
tapering schema over 4 weeks) or abrupt
discontinuation (after continued clopidogrel
therapy for additional 4 weeks) and followed
for 3 months of the composite of cardiac death,
MI, stroke, ST, major bleeding or
rehospitalization. Initially, 3,000 patients
planned to enroll but, the due to the slow
recruitment, study was stopped prematurely
after enrollment of 782 patients; at this point,
tapered discontinuation of chronic clopidogrel
therapy is not superior to abrupt
discontinuation regarding the primary
endpoint in this study.
As recent studies contain more data on the
second-generation DES, clinicians are expecting
that short duration of DAPT would be enough
in the real world. But neither previous clinical
studies nor ongoing randomized trials thus far
have been designed to distinguish outcomes
according to type of stents, several clinical risk
profiles, lesions, and procedural complexities
(i.e., ACS, diabetes mellitus, renal failure, low
ejection fraction, multiple stents, long stents,
left main stents, or bifurcation stents). Further
larger trials with an enough statistical power to
address this specific issue are required
comprising all of these data to establish a firm
policy for DAPT duration.
CONCLUSIONS
Dual antiplatelet therapy with aspirin and a
P2Y12 inhibitor has significantly improved the
outcomes of patients undergoing PCI. Because
of the relative risk and benefit associated with
the use of DESs and DAPT, defining the optimal
duration of DAPT would be very critical in real
practice. Although the latest PCI guidelines
recommended at least 1 year of DAPT after
DES placement, recent randomized clinical
trials have demonstrated that a shorter
duration of DAPT would be safe and effective
than longer treatment, but these trials are still
limited due to a few cardiovascular events,
small-to-intermediate size of study, and
inherent limitations of study designs.
Upcoming results of much larger, double
blind, and randomized clinical trials, with a
higher use of second- and newer generation
DESs will guide the physician in making
informed decisions on the optimal duration of
DAPT for patients receiving DES implantation.
In addition, more data would be required to
define the role of newer generation P2Y12
inhibitors, including ticagrelor and prasugrel,
for diverse clinical settings.
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